脂质体布比卡因在全膝关节置换术周围注射鸡尾酒中的疼痛管理:随机对照试验的系统综述
该系统综述遵循PRISMA指南,检索PubMed和Embase至2025年7月28日,纳入8项随机对照试验共1334例全膝关节置换术患者,评估脂质体布比卡因经周围注射给药的疗效。结果显示5/8研究报道术后早期疼痛改善,尤其术后24小时内,部分试验报道阿片类药物消耗减少和满意度提高,无研究报道劣效结局。结论支持脂质体布比卡因在多模式镇痛路径中的应用,尤其适用于快速通道或门诊方案。
要点
- 脂质体布比卡因经周围注射可改善全膝关节置换术后早期疼痛,尤其术后24小时内。
- 部分试验报道阿片类药物消耗减少和患者满意度提高,无研究报道劣效结局。
- 功能恢复指标(如行走和出院准备)获益不一,安全性特征一致。
核心结论
- 脂质体布比卡因经周围注射可改善全膝关节置换术后疼痛和短期阿片类药物减少,对功能恢复有潜在益处。
- 研究结果支持其用于多模式镇痛路径,尤其适用于快速通道或门诊方案。
研究设计与样本
- 系统综述遵循PRISMA指南,检索PubMed和Embase至2025年7月28日,纳入评估脂质体布比卡因经周围注射用于全膝关节置换术的随机对照试验。
- 纳入标准要求与非脂质体布比卡因或多模式鸡尾酒比较并报告临床或经济结局,排除使用神经阻滞或缺乏随机化的研究。
- 方法学质量采用改良Coleman方法学评分评估,仅纳入高质量研究(mCMS ≥ 85),最终纳入8项随机对照试验共1334例患者。
主要发现
- 8项研究中有5项报道脂质体布比卡因与术后早期疼痛控制改善相关,尤其术后24小时内。
- 部分试验报道阿片类药物消耗减少和患者满意度提高,未增加不良事件。
- 功能恢复指标如行走和出院准备显示获益不一。
- 无研究报告脂质体布比卡因劣效结局,各试验中安全性特征一致且早期镇痛效果良好。
关键数值与推荐
- 仅纳入改良Coleman方法学评分≥85的高质量随机对照试验。
- 8项随机对照试验共1334例患者符合纳入标准。
临床怎么用
- 脂质体布比卡因可作为全膝关节置换术多模式镇痛路径的组成部分,尤其适用于快速通道或门诊方案。
- 临床决策时需注意功能恢复获益不一,应结合患者具体情况个体化应用。
局限性
- 功能恢复指标(如行走和出院准备)的获益在不同试验间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pain remains a major barrier to recovery after total knee arthroplasty (TKA), contributing to delayed mobilization, prolonged opioid use, and extended hospitalization. Liposomal bupivacaine (LB), an extended-release local anesthetic, has gained interest as a component of periarticular injection (PAI) protocols to improve analgesia and reduce opioid use. However, its utility remains debated due to inconsistent findings. This systematic review aimed to assess (1) the effectiveness of LB in improving postoperative pain control; (2) its impact on short-term opioid consumption; and (3) its influence on functional recovery, patient satisfaction, and adverse events. METHODS: This systematic review adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and searched PubMed and Embase through July 28, 2025, for randomized controlled trials evaluating LB delivered via PAI in patients undergoing TKA. Inclusion criteria required comparison with nonliposomal bupivacaine or multimodal cocktails and reporting of clinical or economic outcomes. Studies using nerve blocks or lacking randomization were excluded. Methodologic quality was assessed using the modified Coleman Methodology Score (mCMS), and only high-quality studies (mCMS ≥ 85) were included. There were eight randomized controlled trials encompassing 1,334 patients that met inclustion criteria. RESULTS: Use of LB was associated with improved early postoperative pain control in five of eight studies, particularly within the first 24 hours postoperatively. Several trials also reported reductions in opioid consumption and higher patient satisfaction without increased adverse events. Functional recovery metrics, such as ambulation and discharge readiness, showed variable benefit. There was no study that reported inferior outcomes with LB. Across trials, LB demonstrated a consistent safety profile and favorable early analgesic effects. CONCLUSIONS: Liposomal bupivacaine administered via PAI provides improvements in postoperative pain and short-term opioid reduction after TKA, with potential benefits on functional recovery. These findings support its role in multimodal pain pathways, particularly in fast-track or outpatient protocols. LEVEL OF EVIDENCE: Level I.
引用
- Ng MK, Mastrokostas LE, Mastrokostas PG, et al. Liposomal Bupivacaine in Periarticular Injection Cocktails for Pain Management After Total Knee Arthroplasty: A Systematic Review of Randomized Controlled Trials. J Arthroplasty. 2026. PMID: 42542307. doi:10.1016/j.arth.2026.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。